Le Lézard
Classified in: Health
Subjects: AVO, CFG

The Advisory Council on the Implementation of National Pharmacare recommends Canada implement universal, single-payer public pharmacare


Canada's current patchwork of thousands of private and public prescription plans is not sustainable

OTTAWA, June 12, 2019 /CNW/ - The Advisory Council on the Implementation of National Pharmacare (the Council) is recommending that Canada implement universal, single-payer, public pharmacare.

The Council recommends the federal government work in partnership with provincial and territorial governments to establish a universal, single-payer public system of prescription drug coverage in Canada to ensure everyone has access to the drugs they need to maintain their physical and mental health. The Council also recommends the establishment of a Canadian drug agency, which would be responsible for developing a national list of prescription drugs (the formulary) beginning with an initial formulary of common or so-called essential medicines by January 1, 2022. The Council recommends that this initial formulary expand to a fully comprehensive formulary, to be in place no later than January 1, 2027.

Universal, single-payer public pharmacare will provide access to prescribed medicines for all Canadians, including the estimated one in five who are either uninsured or underinsured. A national formulary will ensure the same medicines are offered right across Canada. The Council is recommending that pharmacare be portable for Canadians wherever they travel or live within Canada; that there be a separate pathway, with dedicated funding, for expensive drugs for rare diseases; and that the approval process for drugs be further streamlined so Canadians can get faster access to new, innovative drugs.

Universal, single-payer public pharmacare will result in better value for money and substantial savings for governments, businesses, and individual Canadians. Once implemented, pharmacare's stronger negotiating power, lower administrative costs, as well as other improvements will save taxpayers an estimated $5 billion annually. Savings for individual Canadians and their families will be significant and tangible. Canadian families will save, on average, $350 per year. Pharmacare will also provide businesses with much-needed relief from the high and growing cost of prescription drug insurance. The average business owner who provides drug coverage will save over $750 annually per employee. The Council recommends that Canadians and employers continue to be able to purchase private drug insurance as a form of supplementary insurance to national pharmacare.

The Council heard from thousands of Canadians and found a strongly shared belief that everyone in Canada should have access to prescription drugs based on their need and not their ability to pay, in a manner that is fair and sustainable.

The delivery of the report marks the completion of the Council's mandate. It is the product of discussions with Canadians, provincial and territorial governments, Indigenous governments and representative organizations, patients, labour, business, industry and other experts in relevant fields.

Quotes

"The time for universal, single-payer public pharmacare has come. This is our generation's national project: better access to the medicines we need, improved health outcomes, and a fairer and more sustainable prescription medicine system. Let's complete the unfinished business of universal health care. That can be our promise, and our legacy, to each other and to all future generations."

Dr. Eric Hoskins
Chair, Advisory Council on the Implementation of National Pharmacare

Quick Facts

Related Products
Backgrounder 
Statement from the Government of Canada on the Final Report from the Advisory Council on the Implementation of National Pharmacare
Advisory Council on the Implementation of National Pharmacare Interim Report
Interim Report
What We Heard Report

 

SOURCE Health Canada


These press releases may also interest you

19 avr 2024
Remedium Healthcare Products is proud to announce the launch of NuVeria Labs' revolutionary Sacral Silicone Dressing, now available for purchase on Amazon, bringing advanced wound care solutions directly to consumers' doorsteps. Designed to address...

19 avr 2024
Getting specialty medications into...

19 avr 2024
Arthrex, a global leader in minimally invasive surgical technology, has once again taken home prestigious medals for product innovation at the 37th annual Edison Awards. "This product, along with our other innovations,...

19 avr 2024
Aligned with the trend of immersive water therapy in 2024, Baros Maldives' Serenity Spa stands out as an oasis of indulgent spa and beauty rituals, boasting a 50-year legacy of luxury. Nestled within a tranquil sanctuary amidst the lush Maldivian...

19 avr 2024
Oragenics, Inc. , a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it received a notice (the "Notice") from the NYSE American LLC (the "NYSE American") dated April...

19 avr 2024
Building on a successful phase one in which STChealth proved that the Universal Patient Identifier (UPI)?powered by Experian Health's Universal Identity Manager (UIM) and NCPDP Standardstm?can accurately identify patients across multiple datasets in...



News published on and distributed by: